JPRN-UMIN000023120已完成1 期
Open-label, dose-escalating clinical trial of Survivin-responsive conditionally replicative adenovirus (Surv.m-CRA-1) by local administration to evaluate the safety / tolerability and preliminary efficacy in patients with advanced solid tumors (Phase I trial). - Phase I clinical trial of a local administration of Survivin-responsive conditionally replicative adenovirus (Surv.m-CRA-1) in patients with advanced solid tumors.
Department of Gene Therapy and Regenerative Medicine, Graduate School of Medical and Dental Sciences, Kagoshima university0 个研究点目标入组 9 人开始时间: 2016年7月11日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 10years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with the following illness: Severe heart disease, respiratory disease, digestive disease or liver disease. Uncontrolled diabetes Infectious disease that needs continuous treatment 2) A history of allergic reactions to penicillin, pork or beef (including milk) 3) Ongoing illness that requires immunosuppressant or corticosteroid administration 4) Currently active or past malignancies within the past five years 5) Uncontrollable fever or pain from the tumor 6) Pregnant, breast-feeding or woman with positive pregnancy test within 1 year after menopause. 7) Treated with non-approved drug within 4 weeks of study entry.
研究者
相似试验
进行中（未招募）
1 期
A study to find a safe dose of volasertib given in addition to standard salvage chemotherapy in children (age 3 months to less than 18 years) with acute myeloid leukaemia, in whom front-line chemotherapy failedPaediatric AML after first-line failureEUCTR2015-004625-14-DEBoehringer Ingelheim Pharma GmbH & Co. KG99,999
进行中（未招募）
1 期
A study to find a safe dose of volasertib given in addition to standard salvage chemotherapy in children (age 3 months to less than 18 years) with acute myeloid leukaemia, in whom front-line chemotherapy failedAcute Myloid LeukaemiaEUCTR2015-004625-14-NLBoehringer Ingelheim bv52
进行中（未招募）
1 期
A study to find a safe dose of volasertib given in addition to standard salvage chemotherapy in children (age 3 months to less than 18 years) with acute myeloid leukaemia, in whom front-line chemotherapy failedEUCTR2015-004625-14-DKBoehringer Ingelheim Pharma GmbH & Co. KG52
进行中（未招募）
1 期
A study to find a safe dose of volasertib given in addition to standard salvage chemotherapy in children (age 3 months to less than 18 years) with acute myeloid leukaemia, in whom front-line chemotherapy failedEUCTR2015-004625-14-BESCS Boehringer Ingelheim Comm.V99,999
进行中（未招募）
1 期
A study to find a safe dose of volasertib given in addition to standard salvage chemotherapy in children (age 3 months to less than 18 years) with acute myeloid leukaemia, in whom front-line chemotherapy failedAcute myeloid leukaemia after failure of front-line therapy in paediatric patientsEUCTR2015-004625-14-ITBoehringer Ingelheim Italia S.p.A.52